Suzhou Hepathera Biotech Co., Ltd.
Clinical trials sponsored by Suzhou Hepathera Biotech Co., Ltd., explained in plain language.
-
New shot combo aims to silence hepatitis b virus
Disease control OngoingThis study tests two experimental injections, HT-101 and HT-102, in 60 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if the combination can lower hepatitis B surface antigen (HBsAg) to undetectable levels and keep the virus unde…
Phase: PHASE2 • Sponsor: Suzhou HepaThera Biotech Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New injections aim to control hepatitis b in early trial
Disease control OngoingThis study tests two experimental injections, HT-101 and HT-102, in 86 adults with chronic hepatitis B who are already on standard antiviral medication. The goal is to see if adding these injections is safe and how the body processes them. Participants receive the injections ever…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou HepaThera Biotech Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:51 UTC